Volume 10, Issue 3 (9-2022)                   JoMMID 2022, 10(3): 146-148 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mostafavi E. How Will the COVID-19 Pandemic End?. JoMMID 2022; 10 (3) :146-148
URL: http://jommid.pasteur.ac.ir/article-1-501-en.html
Department of Epidemiology and Biostatics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (1060 Views)
What has happened in the world since the pandemic began?
More than two years after the COVID-19 pandemic outbreak, the status of the disease is still unclear to us. Up to August 1, 2022, the disease has killed about 6.4 million people worldwide, although the actual death toll is estimated to be three times more than the official death toll [1]. During this time, safe vaccines with high efficacy against the virus have been developed, methods of viral transmission and pathogenicity are better understood, and more effective treatments have been proposed that have helped better control the disease over time. A significant percentage of the world's population has acquired the infection at least once, more than 65% of the world's population has received at least one dose of a COVID-19 vaccine, and about 25% have received at least one booster dose of the COVID-19 vaccine. More than 12 billion doses have been administered globally, with 5.5 million added daily. However, the vaccine distribution is inequitable, and in low-income countries, only about 20% of people have received at least one dose of the vaccine [2].
Full-Text [PDF 450 kb]   (421 Downloads)    
Type of Study: Letter to the Editor | Subject: Epidemiologic studies including microbial genotyping, phenotyping and serotyping
Received: 2022/10/11 | Accepted: 2022/09/19 | Published: 2022/10/12

1. J. Wise. COVID-19: Global death toll may be three times higher than official records, study suggests, British Medical Journal Publishing Group, 2022. [DOI:10.1136/bmj.o636]
2. Coronavirus (COVID-19) Vaccinations: Our World in Data; 2022 [updated July 8, 2022. Available from: https://ourworldindata.org/covid-vaccinations.
3. W. Wen, C. Chen, J. Tang, C. Wang, M. Zhou, Y. Cheng, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19; a meta-analysis. Ann Med. 2022; 54 (1): 516-23. [DOI:10.1080/07853890.2022.2034936]
4. Worldometer. COVID-19 coronavirus pandemic. 2022. Available at: https://www.worldometers.info/coronavirus.
5. A. Hamady, J. Lee, Z.A. Loboda. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection. 2022; 50 (1): 11-25. [DOI:10.1007/s15010-021-01664-z]
6. R. Rubin. COVID-19 vaccines vs variants-determining how much immunity is enough. Jama. 2021; 325 1241-3. [DOI:10.1001/jama.2021.3370]
7. M. Eisenhut, J.I. Shin. COVID-19 vaccines and coronavirus 19 variants including alpha, delta, and omicron: present status and future directions. Life Cycle. 2022: 2. [DOI:10.54724/lc.2022.e4]
8. Q. Wang, Y. Guo, S. Iketani, M.S. Nair, Z. Li, H. Mohri, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4, & BA. 5. Nature. 2022; 608 (7923): 603-8. [DOI:10.1038/s41586-022-05053-w]
9. A. Katzourakis. COVID-19: endemic doesn't mean harmless. Nature. 2022; 601: 485. [DOI:10.1038/d41586-022-00155-x]
10. A.G. Mtewa, A. Amanjot, F. Lampiao, H. Okella, A. Weisheit, C.U. Tolo, et al. SARS-CoV-2 vaccine development, Coronavirus Drug Discovery, Elsevier, 2022, pp. 227-247. [DOI:10.1016/B978-0-323-85156-5.00046-8]
11. J.M. Orient. Negative Evidence: Antibody-Dependent Enhancement. J Am Physicians Surg. 27 (2022) 2-6.
12. Haque A, B Pant A. Mitigating COVID-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. J Autoimmun. (2022); 127: 102792. [DOI:10.1016/j.jaut.2021.102792]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.